WithdrawnPhase 2NCT03950037

SANCC: Clinical Trial Early Intervention

Studying Cysticercosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Oregon Health and Science University
Principal Investigator: Seth E O'Neal, MD MPH
Oregon Health and Science University
Intervention: Albendazole(drug)
Eligibility: 2 years · All sexes
Timeline: 2022 – 2023

Collaborators

Universidad Peruana Cayetano Heredia · National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03950037 on ClinicalTrials.gov

Other trials for Cysticercosis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001205
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Cysticercosis →

← Back to all trials